Member Info for Basser1

Your beginning to make a mountain out of a molehill.
GSK has only had Sierra assets for a couple of months - get real.

Thanks elap
You do not often see the word ‘dramatic’ in scientific papers and in this case it is for possible triple combo treatment ( including SRA737) of Small Cell Lung Cancer.
Brilliant!

The global solid tumour Cancer Treatment market was valued at 121Bn US dollars in 2018 and is expected to reach 424.6 Bn U S Dollars by 2027, expanding at a CAGR of 15% from 2019 to 2027.

This is just the beginning for SRA 737. Potential is enormous with plenty of evidence that when administered in combo can lethally kill cancer cells with a TP 53 mutation. That’s approx 50% of all solid tumour cancers ie all the major cancers. My view is that this was what GSK was after when sealing the Sierra deal. The enormity of this potential new combo treatment has yet to sink in.

So the shadow that Dilley cast over SRA737 has now gone and GSK are free to bring it forward into broad sunlit uplands. Hope now to see development of SRA737 at pace.

Utah - Your posting record seems to put you in the same category.

Seemed some people panicked because share price went up slightly. Ulterior motives perhaps.

Intriguing. Hope it does not take 53 years though!

Nice.

As I said the other day, I sense there are negotiations going on. Keep the share price stable ( ie low as far as I see it) for negotiations and maximise profits for PH clients. Very probably wrong as usual.

Yep. Sareum 60,000,000 shares in issue and 17,000 shares traded today ie around 0.028%. Most sitting tight and waiting. Not surprised given news flow that could start at any time.GLA

Gunner - I’m fairly sure you cannot apply for Agile funding until you provide evidence of clinical low toxicity results.
The more I think about it, It could make some sense for GSK to come after Sareum sooner rather than later. SRA 737 would all be under one roof - Sareum’s licence deal is still lucrative enough to be seen as a valuable acquisition. SDC1801 is at the stage now where pharmas have to make a decision to whether to make an offer early in the hope of getting a better deal. GSK are active in seeking to develop more pipeline assets and they have got the cash to spend. Why wait and risk a more expensive deal later for SDC1801 when you can maybe bag SRA 737 and SDC 1801.in one big deal. Pure conjecture on my part. But the pattern of trading over the last month or so suggests to me that something is up.

Cobalt,- volumes of trades are low -buying and selling. Most shareholders sitting on their hands and waiting for news. My view right or wrong is that the share price is being controlled in a narrow price range - necessary to form a stable basis for negotiations.

Maidit - SRA 737 is the molecule that gets me most excited at the moment - it has already proved its effectiveness in early/mid clinical trials and has a proven safety record. And there is plenty of scientific evidence to suggest that it will be even better in combination with a range of molecules. The Solid Tumour treatment market is massive now and will continue to grow. SRA 737 if successful - and I am confident it will be -will be very lucrative for Sareum for many years to come. It can provides us with some comfort whilst the two SDC molecules commence their journeys into trials.GLA

Baton - there are some fiduciary investigations going on at the moment re the terms of the GSK merger but my view is that the institutions will vote it through. However until then, I suppose there is always a chance of another bidder appearing on the scene - can this still happen?

Belhus - well I think SRA737 has been hidden away (shelved for two years now. I assume your earlier posts on twitter were not deleted? If so and they have only been deleted since the merger announcement , you can draw your own conclusions.

Brightly/ Krone - thought the same thing this morning - a GSK takeover in the not too distant future. That would be great but not at the price they agreed with Sierra Oncology, which in my view undervalues that deal to the detriment of shareholders. I am half expecting a low bid (from ant interested Pharma) to test the Board and Shareholders. The potential of the next generation assets would possibly then trigger a number of counter bids. Just guessing, but we all need to think about the range of options that could occur. GLA

Sorry Scheck been walking the dog. Yes. Just wondered why the headline focused on SRA737 but the text was mainly about Monolitinib and the merger.

Sorry messed up link. Can anyone sort it please?

https://www.life-sciences-europe.com/product/sra737-chk1-inhibitor-sierra-oncology-inc-nasdaq-srra-2001-34142.htmlJust intrigued by the heading. Highlights the GSK press release re the Sierra Oncology merger.?